Compare · COR vs MEDS
COR vs MEDS
Side-by-side comparison of Cencora Inc. (COR) and DataMeds AI Inc. (MEDS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COR and MEDS operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- COR is the larger of the two at $63.07B, about 6448.4x MEDS ($9.8M).
- MEDS has been more active in the news (9 items in the past 4 weeks vs 3 for COR).
- COR has more recent analyst coverage (25 ratings vs 1 for MEDS).
- Company
- Cencora Inc.
- DataMeds AI Inc.
- Price
- -
- -
- Market cap
- $63.07B
- $9.8M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 3
- 9
- Recent ratings
- 25
- 1
Cencora Inc.
CoreSite Realty Corporation (NYSE:COR) delivers secure, reliable, high-performance data center, cloud access and interconnection solutions to a growing customer ecosystem across eight key North American markets. More than 1,375 of the world's leading enterprises, network operators, cloud providers, and supporting service providers choose CoreSite to connect, protect and optimize their performance-sensitive data, applications and computing workloads. Our scalable, flexible solutions and 460+ dedicated employees consistently deliver unmatched data center options  all of which leads to a best-in-class customer experience and lasting relationships.
DataMeds AI Inc.
DataMEDS AI, Inc. (NASDAQ:MEDS), formerly Wellgistics Health, Inc., is a healthcare company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units through its health information technology platforms to deliver a better experience for consumers and providers. Headquartered in Tampa, Fla., DataMEDS incorporates its EinsteinRx artificial intelligence platform and PharmacyChain blockchain-enabled smart contracts platform into the Health Lives Here mobile application from Tollo Health, LLC, and its pharmacy-related Corexa Health subsidiary provides pharmacy dispensing and pharmacy-related services, including distribution of products developed by Tollo Health. DataMEDS also owns Helomics Corporation, a Pittsburgh, PA -based commercial clinical molecular diagnostics laboratory focused on the ChemoFx Assay chemotherapy selection diagnostics test that aims to help oncologists make chemotherapy treatment decisions.
Latest COR
- Gabelli To Host 8th Annual Healthcare Symposium
- SEC Form 8-K filed by Cencora Inc.
- Cencora to Acquire American Oncology Network to Strengthen Support of Community Oncology
- SEC Form 4 filed by Cencora Inc.
- SVP & Chief Accounting Officer Krikorian Lazarus sold $298,935 worth of shares (986 units at $303.18) as part of a pre-agreed trading plan (SEC Form 4)
- Cencora Announces Date and Time for Fourth Quarter Fiscal 2026 Earnings Release
- New insider Sanchez Robert E claimed ownership of 197 shares (SEC Form 3)
- Cencora Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Cencora Elects Robert E. Sanchez to Its Board of Directors
- Director Greenberg Lon R sold $411,264 worth of shares (1,280 units at $321.30), decreasing direct ownership by 7% to 17,128 units (SEC Form 4)
Latest MEDS
- DataMEDS AI Enters Into Agreement for Commercial Supply of Six Peptides Recommended by FDA Advisory Committee
- DataMEDS AI Establishes "Health Lives Here" Community Respiratory Program for Corexa Health Pharmacy Network
- Datavault AI Signs Non-Binding Letter of Intent to Acquire a 19.9% Equity Stake in DataMEDS AI in Consideration of an Expanded Technology License
- DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies
- DataMeds Regains Compliance With NASDAQ Listing Standards
- DataMeds Applauds FDA's Proposed Interim Access Policy for Compounding Using Certain Peptides and Provides Corexa Health's Peptides Roadmap
- DataMEDS Si Licenses U.S. Rights To Reboot Health AI's Direct-To-Consumer GLP-1 Weight Management Platform
- DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology Division
- DataMEDS SI Announces Helomics Receives Medicaid Coverage Policy For Chemofx(R) Assay In Gynecologic Cancers
- Datameds AI Files DBAs Datameds SI And Corexa Health SI And Reminds Shareholders Of Record As Of August 7, 2026 Of Dream Bowl Meme Coin I Payment